suberoyl bis-hydroxamic acid has been researched along with Carcinoma, Medullary in 1 studies
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ning, L | 1 |
| Greenblatt, DY | 1 |
| Kunnimalaiyaan, M | 1 |
| Chen, H | 1 |
1 other study available for suberoyl bis-hydroxamic acid and Carcinoma, Medullary
| Article | Year |
|---|---|
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Medullary; Caspas | 2008 |